Intermediate for Venetoclax. Venetoclax (trade name Venclexta) is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality. Venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. Venetoclax has been approved by US FDA om April 11, 2016.

Specifications

Product Name:                  4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde

Synonyms:                         N/A

CAS Number:                     1228837-05-5

Molecular Weight:            248.7517

Molecular Formula:          C15H17ClO

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               O=CC1=C(CC(CC1)(C)C)c1ccc(cc1)Cl